- Stocks
- Pharma & Healthcare
- Trinity League
Trinity League share price
NSE: TRINITYLEAPharma & HealthcareCapital Markets
Trinity League at a glance
With a market capitalisation of ₹8 Cr, it ranks 3962nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Capital Markets.
Its return on equity was −5.8% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹0 Cr (−30.8% year on year) and net profit ₹0 Cr (−61.9%), on a consolidated basis. Promoters held 61.01% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹8 CrRank 3962 on NSE
- Price to book
- 3.58×FY26
- EPS (TTM)
- −₹0.10to Q4 FY26
- ROE
- −5.8%FY26
- ROCE
- −5.8%FY26
- Debt to equity
- 0FY26
- Net profit margin
- −86.2%FY26
- Book value / share
- ₹3.40FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Trinity League quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | ₹0 Cr | — | ₹0 Cr | — | — | — | ₹0 Cr |
| Revenue YoY | — | — | — | — | — | — | — | −30.8% |
| Net profit | −₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr |
| Net profit YoY | — | — | −300.0% | — | — | — | — | −61.9% |
| Net margin | — | −500.0% | — | 80.8% | — | — | — | 44.4% |
| EPS | −₹0.51 | −₹0.06 | −₹0.08 | ₹0.26 | −₹0.10 | −₹0.03 | −₹0.07 | ₹0.10 |
Trinity League financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Operating profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | −₹0 Cr |
| Net profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | −₹0 Cr |
| EPS (₹) | −₹1.00 | ₹0.00 | ₹0.00 | −₹3.00 | ₹0.00 | ₹0.00 |
| Cash from operations | ₹1 Cr | ₹0 Cr | −₹2 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹2 Cr | ₹2 Cr | ₹6 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
Trinity League shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 61.01% | 61.01% | 61.01% | 61.01% | 61.01% | 61.01% |
| Non-institutions | 38.99% | 38.99% | 38.99% | 38.99% | 38.99% | 38.99% |
Trinity League vs peers
The listed Pharma & Healthcare companies nearest to Trinity League by market capitalisation.
Ask anything about Trinity League
Pivot answers on the live chart with evidence you can check, and tests strategies against TRINITYLEA's own history. Try: “Why has TRINITYLEA moved over the last three months?” · “Backtest a 50-day moving-average crossover on TRINITYLEA over five years” · “Compare TRINITYLEA with BROACH on margins and valuation”
Frequently asked questions about Trinity League
What is the market cap of Trinity League?
Trinity League's market capitalisation is ₹8 Cr (₹8 Cr) at the 22 Oct 2026 close, ranking 3962nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Trinity League?
Return on equity was −5.8% in FY26 and return on capital employed was −5.8% in FY26 (consolidated figures).
Is Trinity League a debt-free company?
Trinity League is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Trinity League's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Trinity League reported revenue of ₹0 Cr, −30.8% year on year, and net profit of ₹0 Cr, −61.9% year on year.
What is the shareholding pattern of Trinity League?
As of 30 Jun 2026: promoters 61.01%, non-institutions 38.99%.
Who are Trinity League's competitors?
The listed Pharma & Healthcare companies closest to Trinity League by market cap are Broach Lifecare, Clinitech Labor, Genomic Valley, Adline Chem Lab, Unjha Formula and Dr Lalchandani.
Is Trinity League a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Trinity League's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TRINITYLEA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with T · all NSE stocks · this page as text